Cisplatin resistance and pd-l1

Author: ztvw

August undefined, 2024

WebApr 13, 2024 · Consequently, miR-196a released from exosomes can confer cisplatin resistance to cancer cells by novel binding targets, CDKN1B and ING5, demonstrating that miR-196a could be a potential predictor ... WebAug 3, 2024 · Background: Non-small cell lung cancer (NSCLC) cells derived intracellular and extracellular programmed cell death ligand 1 (PD-L1) promoted cancer progression and drug resistance, and facilitated tumor immune evasion. However, the detailed molecular mechanisms are still largely unknown.

A highly annotated database of genes associated with platinum …

WebOct 13, 2024 · For example, cisplatin resistance sometimes correlates with the presence of wild type TP53 . ... High expression of CD274/PD-L1 combined with low expression of the histone deacetylase, ... WebPD-L1 in cancer cells, PD-L1 in TILs, and PD-1 in TILs took up 59.1%, 47.0%, and 60.6%, respectively. The data indicated that both dMMR and PD-L1 overexpression resulted … onslow golf course

Comparative study of the PD-L1 expression and CD8+ tumor …

WebCisplatin is one of the most effective broad-spectrum anticancer drugs. Its effectiveness seems to be due to the unique properties of cisplatin, which enters cells via multiple … WebCisplatin is one of the most effective broad-spectrum anticancer drugs. Its effectiveness seems to be due to the unique properties of cisplatin, which enters cells via multiple … WebApr 11, 2024 · BackgroundProgrammed cell death-ligand 1 (PD-L1) inhibitors plus chemotherapy have made substantial progress in extensive-stage small-cell lung cancer (ES-SCLC), but the survival benefit is still limited. This study aimed to evaluate the preliminary efficacy and safety of camrelizumab plus platinum-irinotecan (IP/IC) followed … ioffe-prichard

The relationship between the PD-1/PD-L1 pathway and DNA …

Investigating PD-1/PD-L1 Checkpoint Inhibition as a …

WebNov 15, 2024 · Abstract. Accumulating evidence indicates that a ligand of programmed cell death receptor-1 (PD-L1) participates in the progression and recurrence of multiple malignancies, including osteosarcoma. Nevertheless, the role of PD-L1 in chemoresistance development is not fully understood. WebCisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells Immune tolerance is one of the leading causes of chemotherapy resistance in carcinoma cases. ioffe-pritchard磁阱WebSep 9, 2016 · Here we report that cell-intrinsic expression of PD1 and PD-L1, two immune checkpoints, is required for sustained expansion of SCLC cells under cisplatin selection. Indeed, PD1 and PD-L1 were expressed at a higher level in lung cancer cell lines, tumor tissues, and importantly, in SCLC cells resistant to cisplatin (H69R, H82R), when … ioffe-pritchard trap

"WebPD-L1 high expression was observed at prespecified expression levels of 5% of all cells in a section that included at least 100 evaluable tumor cells. 10 To evaluate the CD8+TIL … " - Cisplatin resistance and pd-l1

Cisplatin resistance and pd-l1

miR‑576‑3p overexpression enhances cisplatin sensitivity of …

WebApr 14, 2024 · Hypoxia also upregulates the expression of PD-1 ligand 1 (PD-L1) on MDSCs, macrophages, dendritic cells, ... Guo Q et al (2024) Hypoxia exposure induced cisplatin resistance partially via activating p53 and hypoxia inducible factor-1α in non-small cell lung cancer A549 cells. Oncol Lett 16:801–808. WebCAFs-derived IL-6 could upregulate CXCR7 in esophageal squamous cell carcinoma and promote resistance to cisplatin via the JAK/STAT3 pathway (Qiao ... T cell receptor-mediated activation rapidly induces PD-1 expression. PD-L1/PD-1 can be regulated by the following signaling pathways in the TME: PI3K/AKT pathway, NF-κB pathway, WNT …

Did you know?

WebOct 21, 2024 · Knockdown of KIFC1 by siRNA increased the sensitivity to cisplatin in BC cells. Kaplan-Meier analysis indicated that prognosis was poor among KIFC1 -positive BC patients treated with cisplatin-based chemotherapy. Immunohistochemistry showed that KIFC1 -positive cases were associated with PD-L1-positive cases. WebPatients were randomized (1:1:1) to receive one of the following treatments: pembrolizumab as a single agent; pembrolizumab, carboplatin or cisplatin, and FU; or cetuximab, carboplatin or ...

WebThe interaction between programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) inhibits T-cell activation and proliferation. 4, 5 Several previous studies have reported that PD-L1 overexpression is a predictor of a poor clinical outcome in patients with NSCLC. 6 – 8 On the other hand, PD-L1 overexpression has been shown to be correlated with an … http://mars.gmu.edu/handle/1920/13265?show=full

WebCisplatin may also cause upregulation of tumor cell PD-L1, which may in part explain the additive antitumor activity of cisplatin and PD-L1/PD-1 blockade. This information will help in interpreting results of ongoing clinical trials combining these agents, and for comparison of potential future therapeutic combinations for the treatment of head ... WebNov 4, 2024 · These 13 genes identify a variety of cisplatin-resistance mechanisms including increased transport and detoxification of cisplatin, and mis-regulation of the epithelial to mesenchymal transition. Conclusions We identified gene signatures in resistant TNBC subtypes indicative of mechanisms of cisplatin.

WebSep 9, 2016 · Here we report that cell-intrinsic expression of PD1 and PD-L1, two immune checkpoints, is required for sustained expansion of SCLC cells under cisplatin …

WebGastric cancer derived mesenchymal stem cells promoted DNA repair and cisplatin resistance through up-regulating PD-L1/Rad51 in gastric cancer 设为首页收藏本站 onslow government jobshttp://mars.gmu.edu/handle/1920/13265?show=full iof femaWebAug 6, 2024 · PD-L1 binding to PD-1 could negatively regulate the signals of T cell receptor (TCR), reducing TCR-mediated proliferation and production of cytokine. PD-L1 is a key protein that regulates the aggregation and clearance of … onslow gpWebThe PD-L1 could reduce the level of cell damage caused by cisplatin. In addition, we found PD-L1 can also up-regulate the expression of P-gp. Mechanistically, PD-L1 activated the PI3K/AKT signaling pathway in which PI3K/AKT pathway inhibition attenuated the upregulation of P-gp. onslow general storeWebMay 1, 2024 · Since PD-L1 expression protects tumor cells from pro-apoptotic drugs, we hypothesized that the PD-1/PD-L1 axis might contribute to the acquisition of resistance … onslow germanyWebApr 14, 2024 · Autophagy Influences Hypoxia, Chemoresistance, and Stem-like Phenotype in Breast Cancer It is known that cancer stem cells are a significant contributor to the development of chemoresistance in breast cancer [ 88, 89, 90, 91 ]. Autophagy enables the survival of CSCs under hypoxia in the tumor microenvironment [ 92 ]. onslow geoffrey hughesWebMar 15, 2024 · Carboplatin-based regimens — For patients who are otherwise candidates for combination chemotherapy but are unable to receive cisplatin (eg, due to renal dysfunction, neuropathy, severe hearing loss, or heart failure), we suggest the combination of gemcitabine plus carboplatin. i offer amnesty at prodromos